



NEW DRUG FAX SHEET

<http://www.samford.edu/go/chipor>

Volume 20 (Issue 15)

July 20, 2015

This issue of *New Drug FAX Sheet* briefly reviews topics that include new drug approvals, new drug formulations, and new drug indications. If you need further information, please contact the Center for Healthcare Innovation and Patient Outcomes Research at (205) 726-2659.

NEW DRUG APPROVALS

Cangrelor (Kengreal, Medicines Co)

Pharmacology: P2Y₁₂ platelet inhibitor.

Indication: Indicated for use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y₁₂ platelet inhibitor and are not receiving a glycoprotein IIb/IIIa inhibitor.

Adverse Drug Reactions: The most common adverse reaction is bleeding.

Dose: 30 µg/kg intravenous (IV) bolus prior to PCI followed immediately by at 4 µg/kg/min infusion for at least 2 hours or duration of procedure (whichever is longer).

Formulation: Single use 10 mL vial containing cangrelor 50 mg as a lyophilized powder for reconstitution.

Warnings/Contraindications: Significant bleeding.

Notes: Administer thienopyridines after cangrelor infusion has been discontinued.

NEW DRUG FORMULATIONS

Buprenorphine and naloxone sublingual tablets (Zubsolv, Orexo)

Pharmacology: Partial opioid agonist.

Indication: Maintenance treatment of opioid dependence.

Dosage form: 2.9 mg/0.71 mg tablet.

Dose: Recommended maintenance dose is 11.4 mg/2.9 mg buprenorphine and naloxone.

Metaxalone (Metaxalone, CorePharma)

Pharmacology:

Indication: Adjunct to rest, physical therapy and other measures for the relief of discomforts associated with musculoskeletal conditions.

Dosage form: 640-mg tablets.

Dose: One tablet 3-4 times daily.

NEW DRUG INDICATIONS

Eltrombopag (Promacta, Novartis)

Pharmacology: Thrombopoietin receptor agonist.

New Indication: Treatment of thrombocytopenia in patients with chronic ITP.

Dose: 50 mg once daily for most adults and pediatric patients (>6 years). Reduce initial dose in patients with hepatic impairment or those with East Asian ancestry. Platelet count should be no greater than 50 X 10⁹/L. Do not exceed 75mg/day.

Preampanel (Fycompa, Eisai)

Pharmacology: Noncompetitive AMPA glutamate receptor antagonist.

New Indication: Treatment of primary generalized tonic-clonic seizures in patients with epilepsy ≥12 years.

Dose: 2 mg once daily in the absence of enzyme-inducing antiepileptic drugs; can increase to a maintenance dose of 8 mg once daily at bedtime.

Zolmitriptan (Zomig, AstraZeneca)

Pharmacology: Serotonin (5-HT)_{1B/1D} receptor agonist (triptan).

New Indication: Acute treatment of migraine with or without aura in adults and pediatric patients ≥12 years.

Dose: Starting dose-2.5 mg; maximum single dose: 5 mg. May repeat dose after 2 hours if needed; do not exceed 10 mg in any 24-hour period.

Prepared by: Maisha Kelly Freeman, Pharm. D, MS, BCPS, FASCP